Polycystic ovary syndrome and metabolic syndrome

References

• The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod.19, 41–47 (2004).
   PubMed Web of Science ®Google Scholar
• Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum. Reprod. Update9, 505–514 (2003).
   PubMed Web of Science ®Google Scholar
• Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J. Clin. Endocrinol. Metab.91, 781–785 (2006).
   PubMed Web of Science ®Google Scholar
• Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Polycystic Ovary Syndrome. Dunaif AGJ, Haseltine F, Merriam GR (Eds). Blackwell Scientific, MA, USA, 377–384 (1992).
   Google Scholar
• Hull MG. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol. Endocrinol.1, 235–245 (1987).
   PubMedGoogle Scholar
• Adams J, Polson DW, Franks, S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br. Med. J. (Clin. Res. Ed.)293, 355–359 (1986).
   PubMed Web of Science ®Google Scholar
• Balen AH, Conway GS, Kaltsas G et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum. Reprod.10, 2107–2111 (1995).
   PubMed Web of Science ®Google Scholar
• Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin. Endocrinol. (Oxf.)51, 779–786 (1999).
   PubMed Web of Science ®Google Scholar
• Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries – a common finding in normal women. Lancet1, 870–872 (1988).
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev.18, 774–800 (1997).
   PubMed Web of Science ®Google Scholar
• Franks S, Gharani, N, McCarthy M. Candidate genes in polycystic ovary syndrome. Hum. Reprod. Update7, 405–410 (2001).
   PubMed Web of Science ®Google Scholar
• Lord J, Wilkin T. Polycystic ovary syndrome and fat distribution: the central issue? Hum. Fertil. (Camb.)5, 67–71 (2002).
   Google Scholar
• Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil. Steril.59, 323–331 (1993).
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N. Engl. J. Med.335, 617–623 (1996).
   PubMed Web of Science ®Google Scholar
• Uilenbroek JT, Woutersen PJ, van der Schoot P. Atresia of preovulatory follicles: gonadotropin binding and steroidogenic activity. Biol. Reprod.23, 219–229 (1980).
   Google Scholar
• Moghetti P, Castello R, Negri C et al. Insulin infusion amplifies 17 α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J. Clin. Endocrinol. Metab.81, 881–886 (1996).
   PubMed Web of Science ®Google Scholar
• Kabir M, Catalano KJ, Ananthnarayan S et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am. J. Physiol. Endocrinol. Metab.288, E454–E461 (2005).
   PubMed Web of Science ®Google Scholar
• Adashi EY. Intraovarian regulation: the proposed role of insulin-like growth factors. Ann. NY Acad. Sci.687, 10–12 (1993).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Sturis J, Byrne MM et al. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J. Clin. Invest.96, 520–527 (1995).
   PubMed Web of Science ®Google Scholar
• Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc. Natl Acad. Sci. USA92, 10619–10623 (1995).
   PubMed Web of Science ®Google Scholar
• American Diabetic Association. Consensus Development Conference on Insulin Resistance. 5–6 November 1997. American Diabetes Association. Diabetes Care21, 310–314 (1998).
   PubMed Web of Science ®Google Scholar
• American Diabetic Association. Diagnosis and classification of diabetes mellitus. Diabetes Care28(Suppl. 1), S37–S42 (2005).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care22, 141–146 (1999).
   PubMed Web of Science ®Google Scholar
• Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet. Gynecol. Surv.59, 141–154 (2004).
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab.84, 165–169 (1999).
   PubMed Web of Science ®Google Scholar
• Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with Type 2 diabetes mellitus. Clin. Endocrinol. (Oxf.)52, 81–86 (2000).
   PubMed Web of Science ®Google Scholar
• Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum. Fertil. (Camb.)3, 101–105 (2000).
   PubMedGoogle Scholar
• Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum. Reprod.16, 1995–1998 (2001).
   PubMed Web of Science ®Google Scholar
• Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J. Clin. Endocrinol. Metab.90, 3236–3242 (2005).
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol. Metab. Clin. North Am.33, 351–375 (2004).
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new worldwide definition. A consensus statement from the International Diabetes Federation. Diabetes Med.23, 469–480 (2006).
   PubMed Web of Science ®Google Scholar
• Lemieux I, Pascot A, Couillard C et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation102, 179–184 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson PW, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation97, 1837–1847 (1998).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Liljenquist DR, Kasza K et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.91, 48–53 (2006).
   PubMed Web of Science ®Google Scholar
• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 1929–1935 (2005).
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism52, 908–915 (2003).
   PubMed Web of Science ®Google Scholar
• Dokras A, Bochner M, Hollinrake E et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet. Gynecol.106, 131–137 (2005).
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA287, 356–359 (2002).
   PubMed Web of Science ®Google Scholar
• Wijeyaratne CN, Waduge R, Arandara D et al. Metabolic and polycystic ovary syndromes in indigenous South Asian women with previous gestational diabetes mellitus. Br. J. Gynaecol.113, 1182–1187 (2006).
   Google Scholar
• Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin. Endocrinol. (Oxf.)57, 343–350 (2002).
   PubMed Web of Science ®Google Scholar
• Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J. Clin. Endocrinol. Metab.88, 1528–1533 (2003).
   PubMed Web of Science ®Google Scholar
• Lakhani K, Prelevic GM, Seifalian AM, Atiomo WU, Hardiman P. Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors. J. Obstet. Gynaecol.24, 613–621 (2004).
   PubMedGoogle Scholar
• Zimmermann S, Phillips RA, Dunaif A et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J. Clin. Endocrinol. Metab.75, 508–513 (1992).
   PubMed Web of Science ®Google Scholar
• Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin. Endocrinol. (Oxf.)45, 623–629 (1996).
   PubMed Web of Science ®Google Scholar
• Wild RA, Grubb B, Hartz A, Van Nort JJ, Bachman W, Bartholomew M. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil. Steril.54, 255–259 (1990).
   PubMed Web of Science ®Google Scholar
• Talbott E, Clarici A, Berga SL et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J. Clin. Epidemiol.51, 415–422 (1998).
   PubMed Web of Science ®Google Scholar
• Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil. Steril.69, 236–241 (1998).
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol. Metab.86, 4666–4673 (2001).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med.342, 836–843 (2000).
   PubMed Web of Science ®Google Scholar
• Lagrand WK, Visser CA, Hermens WT et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation100, 96–102 (1999).
   PubMed Web of Science ®Google Scholar
• Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab.86, 2453–2455 (2001).
   PubMed Web of Science ®Google Scholar
• Blacher J, Benetos A, Kirzin JM, Malmejac A, Guize L, Safar ME. Relation of plasma total homocysteine to cardiovascular mortality in a French population. Am. J. Cardiol.90, 591–595 (2002).
   Google Scholar
• Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol. Obstet. Invest.53, 157–162 (2002).
   PubMed Web of Science ®Google Scholar
• Randeva HS Lewandowski KC, Drzewoski J et al. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.87, 4496–4501 (2002).
   PubMed Web of Science ®Google Scholar
• Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J. Clin. Epidemiol.51, 581–586 (1998).
   PubMed Web of Science ®Google Scholar
• Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. (Oxf.)52, 595–600 (2000).
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet. Gynecol. Scand.71, 599–604 (1992).
   PubMed Web of Science ®Google Scholar
• Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil. Steril.73, 724–729 (2000).
   PubMed Web of Science ®Google Scholar
• Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum. Reprod.15, 24–28 (2000).
   PubMed Web of Science ®Google Scholar
• Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr. Rev.24, 302–312 (2003).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Blackburn G, Higgins M, Lauer R, Perri MG, Ryan D. Physical activity in the prevention and treatment of obesity and its comorbidities: evidence report of independent panel to assess the role of physical activity in the treatment of obesity and its comorbidities. Med. Sci. Sports Exerc.31, 1493–1500 (1999).
   PubMed Web of Science ®Google Scholar
• The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med.157, 2413–2446 (1997).
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation96, 2751–2753 (1997).
   PubMed Web of Science ®Google Scholar
• Kiddy DS, Hamilton-Fairley D, Bush A et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.)36, 105–111 (1992).
   PubMed Web of Science ®Google Scholar
• Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J. Clin. Endocrinol. Metab.90, 729–733 (2005).
   PubMed Web of Science ®Google Scholar
• Gokcel A, Gumurdulu Y, Karakose H et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes. Metab.4, 49–55 (2002).
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. Br. Med. J.327, 951–953 (2003).
   PubMed Web of Science ®Google Scholar
• Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum. Reprod.21, 80–89 (2006).
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev.3, CD003053 (2003).
   Google Scholar
• Moghetti P, Castello R, Negri C et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab.85, 139–146 (2000).
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Wang P, Kobayashi S, Phillips, H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil. Steril.77, 520–525 (2002).
   PubMed Web of Science ®Google Scholar
• Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.61, 946–951 (1985).
   PubMed Web of Science ®Google Scholar
• Maciel GA, Soares Junior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil. Steril.81, 355–360 (2004).
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in Type 2 diabetes mellitus: systematic review and meta-analysis. Arch. Intern. Med.163, 2594–2602 (2003).
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil. Steril.75, 46–52 (2001).
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum. Reprod.19, 510–521 (2004).
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum. Reprod.19, 1323–1330 (2004).
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med.351, 1106–1118 (2004).
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann D, Legro RS et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab.86, 1626–1632 (2001).
   PubMed Web of Science ®Google Scholar
• Teede HJ, Meyer C, Norman RJ. Insulin-sensitisers in the treatment of polycystic ovary syndrome. Exp. Opin. Pharmacother.6, 2419–2427 (2005).
   PubMed Web of Science ®Google Scholar
• Jahanfar S, Eden JA, Nguyent TV. Bulimia nervosa and polycystic ovary syndrome. Gynecol. Endocrinol.9, 113–117 (1995).
   PubMed Web of Science ®Google Scholar
• Homburg R, Lambalk CB. Polycystic ovary syndrome in adolescence – a therapeutic conundrum. Hum. Reprod.19, 1039–1042 (2004).
   PubMed Web of Science ®Google Scholar
• Flagmini C. Long term management of hirsute patients with cyproterone acetate. In: Hirsutism and Endocrine Dermatological Problems. Spona J, Aydinlik S (Eds). Parthenon Press, Carnforth, UK, 29–37 (1988).
   Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab.85, 3161–3168 (2000).
   PubMed Web of Science ®Google Scholar
• Cibula D, Sindelka G, Hill M, Fanta M, Skrha J, Zivny J. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum. Reprod.17, 76–82 (2002).
   PubMed Web of Science ®Google Scholar
• Cibula D, Fanta M, Vrbikova J et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum. Reprod.20, 180–184 (2005).
   PubMed Web of Science ®Google Scholar
• Creatsas G, Koliopoulos C, Mastorakos G. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann. NY Acad. Sci.900, 245–252 (2000).
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gagliardi L, Vicennati V et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin. Endocrinol. (Oxf.)50, 517–527 (1999).
   PubMed Web of Science ®Google Scholar
• Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J. Clin. Endocrinol. Metab.86, 3595–3598 (2001).
   PubMed Web of Science ®Google Scholar
• Ibanez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J. Clin. Endocrinol. Metab.88, 2600–2606 (2003).
   PubMedGoogle Scholar
• Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J. Clin. Endocrinol. Metab.80, 1429–1430 (1995).
   PubMed Web of Science ®Google Scholar
• Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J. Clin. Endocrinol. Metab.79, 1158–1165 (1994).
   PubMed Web of Science ®Google Scholar
• Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. Br. J. Gynaecol.113, 5–14 (2006).
   Google Scholar
• Grodstein F, Manson JE, Stampfer MJ, Willett WC. The discrepancy between observational studies and randomized trials of menopausal hormone therapy. Ann. Intern. Med.140, 764–765 (2004).
   PubMed Web of Science ®Google Scholar